The cases of Mucormycosis have increased rapidly in the country. In the last three weeks, the country has witnessed more than 30,000 cases and nearly 2100 deaths. The disease, which has a mortality rate of 50%, isn’t that uncommon but has evoked strong public concern amid the second wave of COVID-19.
How it is related to COVID-19?
The disease is caused by a set of micro-organisms known as mucormycetes, which are present naturally in the environment, seen mostly in soil and in decaying organic matter like leaves, compost and piles.
In a normal course, our body’s immune system successfully fights such fungal infections. However, we know that COVID-19 affects our immune system. Moreover, the treatment of COVID-19 patients involves the intake of drugs like dexamethasone, which suppress our immune system response. Due to these factors, COVID-19 patients face a renewed risk of failing the battle against attacks mounted by organisms such as mucormycetes.
In addition, COVID patients undergoing oxygen therapy in ICU, where humidifiers are used, are prone to fungal infection because of exposure to moisture.
But this does not mean that every COVID patient will get infected by Mucormycosis. The disease is uncommon in those not having diabetes but can be fatal if not treated promptly. Chances of recovery depend upon early diagnosis and treatment.
According to an advisory issued by the Indian Council of Medical Research, the following conditions in COVID-19 patients increase the risk of mucormycosis infection:
- Uncontrolled diabetes
- Weakening of immune system due to use of steroids
- Prolonged ICU/hospital stay
- Comorbidities/post organ transplant / cancer
- Voriconazole therapy (used to treat serious fungal infections)
According to a study published in the June 2019 edition of Medical Mycology, an Oxford University Press journal, nearly 56% of the surveyed mucormycosis patients were reported as having uncontrolled diabetes. WHO data says that nearly 9% of India’s adult population is suffering from diabetes, which is one of the highest in the world.
Prompt diagnosis and treatment become extremely important in the current scenario when there is panic in the minds of the people related to the disease. In order to create awareness among the healthcare professionals about the diagnosis and treatment, MedPiper Technologies is conducting a live Webinar on Mucormycosis in Covid-19 Patients with Uncontrolled Diabetes on 18th June, Friday, 5 PM. Padma Shri Awardee Dr V Mohan will be the distinguished speaker for the event. All the doctors, medical students & other medical professionals can benefit from the webinar by being aware about handling the disease and patients suffering from it. All the participants will be provided with e-certificates.
Those who are interested in attending the event can register here or may reach out to Soumya TS at firstname.lastname@example.org / Mob: +91 90800 78447.